Payment overview · 2025
General Payments
$1,186.86
14 reported records · 6 companies
Healthcare provider profile · identity verified
Susan C Winterbauer, APN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · ROCKFORD, IL · NPI 1073816013
Verified facts
What the public records show
CMS Open Payments records show Susan C Winterbauer, APN received $1,186.86 in general payments during 2025 across 14 reported records.
AstraZeneca Pharmaceuticals LP accounted for 50.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 160 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $604.07 | 50.9% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $171.54 | 14.4% | 4 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $171.02 | 14.4% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $124.99 | 10.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $100.00 | 8.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.24 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,186.86 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $482.22 | 4 | 2025 |
Source payment records
|
|||||
| OMNIPOD Normalized: omnipod |
Device | Insulet Corporation | $171.02 | 2 | 2025 |
Source payment records
|
|||||
| DEXCOM G7 GSS (161) Normalized: dexcom g7 gss 161 |
Medical Supply | Dexcom, Inc. | $124.99 | 1 | 2025 |
Source payment records
|
|||||
| DEXCOM STELO GLUCOSE BIOSENSOR Normalized: dexcom stelo glucose biosensor |
Not specified | Dexcom, Inc. | $124.99 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $122.86 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $121.85 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $100.00 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.24 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
90 | 25 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
26 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
96 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
111 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
53 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
160 | 34 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 729 | 161 |
| Lisinopril | Lisinopril | 608 | 141 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 596 | 138 |
| Amlodipine Besylate | Amlodipine Besylate | 543 | 130 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 437 | 124 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 406 | 67 |
| Omeprazole | Omeprazole | 398 | 85 |
| Gabapentin | Gabapentin | 343 | 87 |
| Levothyroxine Sodium | Levothyroxine Sodium | 338 | 73 |
| Metoprolol Succinate | Metoprolol Succinate | 295 | 71 |
| Metformin Hcl | Metformin Hcl | 285 | 68 |
| Hydrochlorothiazide | Hydrochlorothiazide | 273 | 70 |
| Tamsulosin Hcl | Tamsulosin Hcl | 265 | 62 |
| Losartan Potassium | Losartan Potassium | 255 | 61 |
| Tramadol Hcl | Tramadol Hcl | 230 | 40 |
| Pantoprazole Sodium | Pantoprazole Sodium | 210 | 43 |
| Furosemide | Furosemide | 203 | 48 |
| Fluticasone Propionate | Fluticasone Propionate | 197 | 58 |
| Trazodone Hcl | Trazodone Hcl | 197 | 50 |
| Potassium Chloride | Potassium Chloride | 187 | 40 |
| Sertraline Hcl | Sertraline Hcl | 170 | 32 |
| Ozempic | Semaglutide | 160 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 159 | 36 |
| Quetiapine Fumarate | Quetiapine Fumarate | 159 | 29 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 147 | 43 |
| Duloxetine Hcl | Duloxetine Hcl | 143 | 32 |
| Pravastatin Sodium | Pravastatin Sodium | 140 | 38 |
| Carvedilol | Carvedilol | 125 | 28 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 122 | 31 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 113 | 30 |
| Mounjaro | Tirzepatide | 111 | 22 |
| Eliquis | Apixaban | 110 | 31 |
| Metformin Hcl Er | Metformin Hcl | 109 | 27 |
| Fluoxetine Hcl | Fluoxetine Hcl | 108 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 105 | 24 |
| Glipizide | Glipizide | 98 | 25 |
| Jardiance | Empagliflozin | 96 | 24 |
| Alendronate Sodium | Alendronate Sodium | 95 | 24 |
| Ibuprofen | Ibuprofen | 95 | 23 |
| Meloxicam | Meloxicam | 95 | 29 |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 90 | 25 |
| Montelukast Sodium | Montelukast Sodium | 88 | 20 |
| Ezetimibe | Ezetimibe | 85 | 28 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 85 | 27 |
| Pregabalin | Pregabalin | 85 | 14 |
| Famotidine | Famotidine | 82 | 20 |
| Spironolactone | Spironolactone | 80 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 74 | 32 |
| Hydralazine Hcl | Hydralazine Hcl | 72 | 22 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 68 | 16 |
| Sumatriptan Succinate | Sumatriptan Succinate | 67 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 66 | 16 |
| Clonidine Hcl | Clonidine Hcl | 61 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 61 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 61 | 15 |
| Simvastatin | Simvastatin | 59 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 59 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 57 | 12 |
| Trulicity | Dulaglutide | 53 | 12 |
| Glipizide Er | Glipizide | 52 | suppressed |
| Lamotrigine | Lamotrigine | 51 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 51 | 32 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 51 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 50 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 50 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 49 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 49 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 46 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 45 | 13 |
| Levetiracetam | Levetiracetam | 45 | suppressed |
| Allopurinol | Allopurinol | 43 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 42 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 41 | 13 |
| Olanzapine | Olanzapine | 41 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 41 | 11 |
| Bupropion Xl | Bupropion Hcl | 38 | suppressed |
| Chlorthalidone | Chlorthalidone | 37 | 12 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 36 | suppressed |
| Etodolac | Etodolac | 36 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 36 | suppressed |
| Prednisone | Prednisone | 35 | 32 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 34 | suppressed |
| Nystatin | Nystatin | 34 | 20 |
| Mirtazapine | Mirtazapine | 33 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 32 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 32 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 32 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 31 | suppressed |
| Calcitriol | Calcitriol | 30 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 30 | 15 |
| Enalapril Maleate | Enalapril Maleate | 29 | suppressed |
| Linzess | Linaclotide | 29 | suppressed |
| Naproxen | Naproxen | 29 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 28 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 28 | 12 |
| Meclizine Hcl | Meclizine Hcl | 28 | 16 |
| Memantine Hcl | Memantine Hcl | 28 | suppressed |
| Tradjenta | Linagliptin | 28 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 26 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 26 | 11 |
| Baclofen | Baclofen | 25 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 25 | suppressed |
| Nifedipine Er | Nifedipine | 25 | suppressed |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 24 | suppressed |
| Finasteride | Finasteride | 24 | suppressed |
| Topiramate | Topiramate | 24 | suppressed |
| Atenolol | Atenolol | 23 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 23 | suppressed |
| Vascepa | Icosapent Ethyl | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Nitroglycerin | Nitroglycerin | 21 | suppressed |
| Novolog Flexpen | Insulin Aspart | 21 | suppressed |
| Primidone | Primidone | 21 | suppressed |
| Glimepiride | Glimepiride | 20 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 20 | suppressed |
| Irbesartan | Irbesartan | 19 | suppressed |
| Risperidone | Risperidone | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 18 | suppressed |
| Alprazolam | Alprazolam | 17 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 17 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 16 |
| Rybelsus | Semaglutide | 16 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Cephalexin | Cephalexin | 14 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 14 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 12 |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Azithromycin | Azithromycin | 11 | 11 |
| Benztropine Mesylate | Benztropine Mesylate | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Lorazepam | Lorazepam | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | 11 |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,186.86 · 14 records | AstraZeneca Pharmaceuticals LP | BREZTRI, Cologuard Collection Kit, DEXCOM G7 GSS (161), DEXCOM STELO GLUCOSE BIOSENSOR, FARXIGA, OMNIPOD, Wegovy, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error